ArticlePharmacological reports : PR2026
The extensive erythrocyte-plasma partitioning of trametinib - implications for pharmacokinetic studies and therapeutic drug monitoring.
Article in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrametinib (TRT) is a kinase inhibitor displaying extensive erythrocyte-plasma partitioning (EPP). Plasma concentrations have been evaluated in most pharmacokinetic studies and for therapeutic drug monitoring (TDM), with controversial outcomes. We investigated EPP to evaluate its impact on TRT pharmacokinetics and laboratory assays.
methodsTRT concentrations were monitored in spiked whole blood, in plasma and erythrocytes separated from spiked whole blood, and in plasma spiked directly. The erythrocyte-plasma partitioning coefficient (Ke/p) was established at 38 °C, room temperature (RT), and 2–8 °C. TRT concentrations and Ke/p were assessed in samples collected from a pediatric patient receiving TRT and in the steady state. Assays were performed using liquid chromatography-mass spectrometry and an in-house method validated for plasma TRT assays.
resultsTRT was chemically stable in whole blood and plasma at RT and 2–8 °C. The TRT content of erythrocytes varied by concentration and storage temperature. At 20 ng/mL, Ke/p increased remarkably at RT and 38 °C, but remained unchanged at 2–8 °C. At 60 ng/mL, Ke/p increased throughout the 4-hour time frame, though to a considerably lesser extent. In in vivo samples, Ke/p showed a strong multivariate correlation with time after dose intake and the product of dose and hematocrit at 7.33–15.7 h postdose (r = 0.987). TRT also exerted temperature-dependent diffusion from erythrocytes into TRT-free plasma.
conclusionsEPP of TRT is related to concentration, temperature, and time in the therapeutic concentration range. Parallel whole blood and plasma TRT assays may therefore be useful for clinical pharmacokinetic studies and TDM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.